Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response

被引：0
|
作者：
Panaccione, Remo [1 ]
Abreu, Maria T. [2 ]
Lazariciu, Irina [3 ]
Mundayat, Rajiv [3 ]
Lawendy, Nervin [4 ]
Salese, Leonardo [4 ]
Woolcott, John C. [4 ]
Sands, Bruce E. [5 ]
Chaparro, Maria [6 ,7 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Inflammatory Bowel Dis Clin, Gastrointestinal Res, Calgary, AB, Canada
[2] Univ Miami, Miller Sch Med, Crohns & Colitis Ctr, Miami, FL 33136 USA
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Collegeville, PA USA
[5] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
[6] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP, Madrid, Spain
[7] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S761
引用
收藏
页码：S351 / S352
页数：2
相关论文
共 50 条
  • [1] Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S351 - S351
  • [2] Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (12) : 1534 - 1544
  • [3] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. GUT, 2018, 67 : A62 - A63
  • [4] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
    Sandborn, William J.
    Lawendy, Nervin
    Danese, Silvio
    Su, Chinyu
    Loftus, Edward V., Jr.
    Hart, Ailsa
    Dotan, Iris
    Damiao, Aderson O. M. C.
    Judd, Donna T.
    Guo, Xiang
    Modesto, Irene
    Wang, Wenjin
    Panes, Julian
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478
  • [5] Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
    Colombel, J. F.
    Osterman, M. T.
    Ibanez, P.
    Thorpe, A. J.
    Zhang, H.
    Lawendy, N.
    Su, C.
    Reinisch, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S098 - S099
  • [6] MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: UPDATED RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
    Colombel, Jean Frederic
    Osterman, Mark T.
    Ibanez, Patricio
    Thorpe, Andrew J.
    Zhang, Haiying
    Lawendy, Nervin
    Su, Chinyu
    Reinisch, Walter
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1199
  • [7] MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
    Colombel, Jean Frederic
    Osterman, Mark T.
    Ibanez, Patricio
    Vermeire, Severine
    Irving, Peter M.
    Gardiner, Sean M.
    Connelly, Susan B.
    Mundayat, Rajiv
    Lawendy, Nervin
    Su, Chinyu
    Reinisch, Walter
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S125 - S126
  • [8] Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
    Biedermann, L.
    Dubinsky, M. C.
    Vermeire, S.
    Fellmann, M.
    Gardiner, S.
    Hur, P.
    Mundayat, R.
    Panes, J.
    Rubin, D. T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I317 - I319
  • [9] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
  • [10] Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
    Biedermann, Luc
    Dubinsky, Marla C.
    Vermeire, Severine
    Fellmann, Marc
    Gardiner, Sean
    Hur, Peter
    Mundayat, Rajiv
    Panes, Julian
    Rubin, David T.
    [J]. INFLAMMATORY BOWEL DISEASES, 2022, : 1370 - 1379
12345